MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Operating Expenses 2011-2026 | NEOG
Annual Operating Expenses Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.48 B | 405 M | 368 M | 184 M | 141 M | 129 M | 124 M | 120 M | 107 M | 96.7 M | 86.6 M | 79.2 M | 68.8 M | 58.7 M | 52 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.48 B | 52 M | 234 M |
Quarterly Operating Expenses Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 111 M | - | 105 M | 571 M | 103 M | - | 105 M | 102 M | 97.6 M | - | 92.3 M | 120 M | 56.2 M | 176 M | 51 M | 48.1 M | 38.3 M | 86.4 M | 38.1 M | 34 M | 31.4 M | 34 M | 32.3 M | 32.8 M | 31.9 M | 32.8 M | 31.9 M | 31.8 M | 30.2 M | 31.8 M | 30.2 M | 30.2 M | 28.5 M | 31.3 M | 29.4 M | 26.7 M | 25.7 M | 26.7 M | 25.7 M | 23.6 M | 22.9 M | 23.6 M | 21.5 M | 21.3 M | 20.6 M | 21.3 M | 20.6 M | 19.8 M | 17.9 M | 19.8 M | 17.9 M | 16.8 M | 16.2 M | 16.8 M | 16.2 M | 14.5 M | 13.6 M | 14.5 M | 13.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 571 M | 13.6 M | 52.6 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.99 B | $ 116.73 | 2.5 % | $ 35.5 B | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
59.5 M | $ 25.1 | 1.09 % | $ 697 M | USA |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
6.71 B | $ 196.39 | 2.82 % | $ 140 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 16.2 | 1.85 % | $ 490 M | USA |
 |
CareDx, Inc
CDNA
|
411 M | $ 17.93 | 1.45 % | $ 955 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
226 M | $ 94.2 | 0.96 % | $ 11.8 B | USA |
 |
DexCom
DXCM
|
1.89 B | $ 65.33 | 3.53 % | $ 25.5 B | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
726 M | $ 15.99 | -0.62 % | $ 172 M |  China |
 |
Co-Diagnostics
CODX
|
50.6 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 107.95 | 0.74 % | $ 8.9 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
20 M | $ 2.0 | 0.25 % | $ 8.85 M | USA |
 |
Illumina
ILMN
|
3.69 B | $ 128.01 | 1.24 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
2.94 B | $ 173.83 | 1.88 % | $ 29.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 275.0 | 2.17 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 80.06 | 2.54 % | $ 5.4 B | USA |
 |
Charles River Laboratories International
CRL
|
607 M | $ 175.68 | 3.62 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
118 M | $ 521.98 | 2.65 % | $ 15.1 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
1.01 B | $ 1 320.64 | 3.99 % | $ 27.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.82 | 1.58 % | $ 446 M | USA |
 |
NeoGenomics
NEO
|
430 M | $ 8.27 | 2.54 % | $ 1.06 B | USA |
|
Biodesix
BDSX
|
106 M | $ 14.44 | -0.65 % | $ 1.87 B | USA |
 |
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
258 M | $ 211.74 | 1.18 % | $ 20.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
600 M | $ 1.47 | 2.15 % | $ 441 M | USA |
 |
PerkinElmer
PKI
|
1.07 B | - | -0.91 % | $ 14.7 B | USA |
 |
Quotient Limited
QTNT
|
106 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Precipio
PRPO
|
11.9 M | $ 28.05 | -1.58 % | $ 45 M | USA |
 |
Personalis
PSNL
|
44.5 M | $ 6.42 | 4.05 % | $ 380 M | USA |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
9.98 M | $ 2.7 | 0.37 % | $ 87.6 K | USA |
 |
Biomerica
BMRA
|
5.64 M | $ 2.16 | - | $ 4.96 M | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.18 | 0.43 % | $ 6.43 M | USA |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | Israel |